Clinical Trial

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
In recent years, growing evidences have demonstrated promising synergistic antitumor effects of radiotherapy combined with immunotherapy. More over, LDRT may enhance the antitumor effect of immunotherapy by altering the tumor immune microenvironment (TIME) and adjusting the immune response. In this study, we will explore the safety and feasibility of LDRT and immunochemotherapy in liver metastatic colorectal cancer. 9-18 participants will be enrolled in this study. All will take part at Daping Hospital, Army Medical University.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-02-23; most recent amendment 2026-04-02.
Trial Details
NCT Number NCT06848465
Lead Sponsor Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions Colorectal Cancer, Liver Metastasis, LDRT
Enrollment 9 participants
Start Date 2025-02-28
Primary Completion 2026-08-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-03